Bipolar Depression Research Review
  • CME
  • CE

Two faculty experts discuss advances in research for bipolar depression and discuss the clinical implications, strengths, limitations, and salient conclusions of the studies.
Sanjay Gupta, MD
Roger McIntyre, MD, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credit
Released: October 28, 2021 Expiration: October 27, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe evidence-based treatment modalities for the management of bipolar depression
  • Identify factors such as side-effects, symptoms and specifiers that impact outcomes and decision-making in bipolar depression treatment


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Sanjay Gupta, MD

Clinical Professor
Department of Psychiatry
SUNY at Buffalo Jacobs School of Medicine
Chief Medical Officer
BryLin Behavioral Health System
Buffalo, New York

Sanjay Gupta, MD has disclosed he has received fees for Non-CME/CE services from AbbVie, Alkermes, Intracelluar, Janssen, Neurocrine, Otsuka, and Sunovion and consulting fees from Intracellular therapies.
Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Roger McIntyre, MD, FRCPC, has disclosed that he has received consulting fees from AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, and Takeda and serves as CEO of Braxia Scientific Corp.


Mark Christiansen, PhD, PA-C
Mark Christiansen, PA, has no relevant conflicts of interest to report.
Aditi Nadkarni, PhD
Aditi Nadkarni, PhD, has no relevant conflicts of interest to report.
Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists engaged in the care of patients with psychiatric illness.


The goal of this activity is to improve the knowledge, competence, and performance of learners to assess pharmacotherapies for bipolar depression.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-229-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 27, 2022. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2021, through October 27, 2022:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides from the essential tremor presentation at the 2022 Movement Disorders+ Summit, from Clinical Care Options (CCO)

Daniel Kremens, MD, JD Released: September 27, 2022

Slides from a presentation that educates clinicians on assessment and treatment of tardive dyskinesia.

Stuart Isaacson, MD Released: September 27, 2022

Slides from a presentation that educates clinicians on surgical therapies in Parkinson’s disease

Marta San Luciano, MD, MS, FAAN Released: September 26, 2022

Slides from a presentation that educates clinicians on adjuntive treatments for advanced Parkinson’s disease.

Rajesh Pahwa, MD Released: September 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings